Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;73(7):1058-1059.
doi: 10.1002/acr.24376. Epub 2021 Jun 4.

Ustekinumab For the Treatment of Giant Cell Arteritis: Comment on the Article by Matza et al

Maxime Samson  1 , Bernard Bonnotte  2
Affiliations
Comment

Ustekinumab For the Treatment of Giant Cell Arteritis: Comment on the Article by Matza et al

Maxime Samson et al. Arthritis Care Res (Hoboken). 2021 Jul.
No abstract available

PubMed Disclaimer

Comment in

  • Reply.
    Matza MA, Fernandes AD, Stone JH, Unizony SH. Matza MA, et al. Arthritis Care Res (Hoboken). 2021 Jul;73(7):1059-1060. doi: 10.1002/acr.24378. Epub 2021 Jun 23. Arthritis Care Res (Hoboken). 2021. PMID: 33161642 No abstract available.

Comment on

References

    1. Matza MA, Fernandes AD, Stone JH, Unizony SH. Ustekinumab for the treatment of giant cell arteritis. Arthritis Care Res (Hoboken) 2021;73:893-7.
    1. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317-28.
    1. Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990-9.
    1. Conway R, O’Neill L, Gallagher P, McCarthy GM, Murphy CC, Veale DJ, et al. Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial. Semin Arthritis Rheum 2018;48:523-8.
    1. Conway R, O’Neill L, O’Flynn E, Gallagher P, McCarthy GM, Murphy CC, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis 2016;75:1578-9.

MeSH terms

LinkOut - more resources